The ECSTATIC feasibility trial compared platelet transfusion triggers of 50 and 90 × 10⁹/L in 50 children on ECMO, supporting a larger definitive trial.
A secondary ECSTATIC analysis examined 161 platelet transfusions in 27 children on ECMO. The median platelet increment was 19 × 10⁹/L. Pathogen-reduced products were
PerfusionGPT AssistantEducation · Research · Global cardiac care
Educational information only. Follow your institution’s clinical protocols. Please do not share patient information. Document search is being connected.